表 1.

奥希替尼再挑战文献总结

Literature review of osimertinib rechallenges

Cases	Age/Gender	EGFR mutation	Onset of ILD	ILD grade	Corticosteroid (dose)	Osi cessation period	Recurrence of ILD	References
EGFR: epidermal growth factor receptor; ILD: interstitial lung disease; Osi: Osimertinib; PSL: Prednisolone; NA: not available; F: female; M: male.
1	32/M	Del 19 T790M	4.5 mon	NA	Yes	NA	No	[14]
2	82/M	Del 19 T790M	8 mon	4	Yes	2 mon	No	[15]
3	60/M	Del 19 T790M	6 wk	3	Yes	NA	Yes	[15]
4	69/F	L858R T790M	55 d	NA	PSL 10 mg/d	15 d	No	[16]
5	32/M	L858R T790M	135 d	NA	Yes	2 mon	No	[17]
6	75/F	Del 19 T790M	64 d	2	PSL 0.5 mg/kg	26 d	No	[18]
7	62/M	Del 19 T790M	82 d	2	Yes	14 d	No	[19]
8	38/M	L858R T790M	31 d	2	No	NA	No	[20]
9	75/F	Del 19 T790M	6 mon	2	Yes	NA	No	[21]
10	73/F	L858R	3.3 mon	1	No	3.2 mon	No	[22]
11	56/M	L858R	1.0 mon	2	PSL 1 mg/kg	1.4 mon	Yes	[22]
12	45/F	Del 19	2.8 mon	2	PSL 1 mg/kg	6.3 mon	No	[22]
13	72/F	Del 19	5.9 mon	1	No	1.4 mon	No	[22]
14	64/F	Del 19	7.7 mon	1	No	14.0 mon	No	[22]
15	39/F	L858R	1.8 mon	2	No	6.2 mon	No	[22]
16	72/F	Del 19	5.6 mon	2	PSL 1 mg/kg	14.7 mon	No	[22]
17	71/F	Del 19	2.7 mon	1	No	15.2 mon	No	[22]
18	58/F	Del 19	8 wk	NA	PSL 1 mg/kg	4 wk	No	[23]
19	65/F	Del 19 T790M L858R	7 wk	NA	PSL 0.5 mg/kg	6 wk	No	[23]
20	64/M	L858R T790M	9 mon	3	PSL 1 mg/kg	14 wk	No	[23]
21	64/M	Del 19	60 d	2	Yes	5 mon	No	Present case